Phase 3 COPD Trial, Recruiting NCT06959095 Sponsor: GlaxoSmithKline Condition: COPD
Back to Copd

Phase 3 COPD Trial, Recruiting

NCT06959095
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 40 and 80 years old (inclusive) at the time of signing the consent form.
  • You have a higher-than-normal level of a type of white blood cell called eosinophils in your blood.
  • You have been diagnosed with moderate to severe COPD (chronic obstructive pulmonary disease) for at least 1 year, confirmed by a breathing test showing specific results.
  • You have had at least 2 moderate flare-ups (exacerbations) or at least 1 severe flare-up of your COPD in the past 12 months.
  • You scored 10 or higher on a standard COPD symptom questionnaire called the CAT (COPD Assessment Test).
  • You are a current or former cigarette smoker with at least 10 pack-years of smoking history (for example, 1 pack per day for 10 years, or 2 packs per day for 5 years).
  • You have been using a combination of three inhaled medications (an inhaled steroid, plus two different types of long-acting inhalers) for at least 6 months before the screening visit.
  • Your body mass index (a measure of body weight relative to height) is at least 16.
  • You are male, or a female who meets the trial's specific eligibility requirements (confirm with trial site).

Who may not be able to join:

  • You have been diagnosed with asthma by a doctor, either now or in the past.
  • You have another significant lung condition where COPD is not considered your main lung problem.
  • You have had pneumonia, a COPD flare-up, or a lower respiratory tract infection in the 4 weeks before your screening visit.
  • You have had lung volume reduction surgery or a procedure involving endobronchial valves, or you are planning to have one.
  • You have been in an active pulmonary rehabilitation (lung exercise) program within the 4 weeks before your screening visit.
  • You need to use supplemental oxygen for more than 12 hours per day.
  • You have a serious heart condition related to lung problems, such as right heart failure or severe high blood pressure in the lungs.
  • You need to use a breathing support machine at night or during the day (such as BiPAP or CPAP) due to a build-up of carbon dioxide in your blood.
  • You have an unstable heart condition or an irregular heartbeat.
  • You have had a known parasitic infection within the 6 months before your screening visit.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: GSK Clinical Trials, GlaxoSmithKline

Phone: 877-379-3718

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Registry
ClinicalTrials.gov
Start date
20 June 2025
Est. completion
20 August 2029

Where this trial is recruiting

🇨🇳 China 🇯🇵 Japan 🇺🇸 United States

Primary endpoints

Annualized Rate of Moderate/Severe Exacerbations

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov